摘要
目的 :探讨 3种不同的循环抗原 (CAg)检测方法在日本血吸虫病人经吡喹酮治疗后疗效考核的应用价值。方法 :采用单克隆抗体 (MAb)JPG3,分别建立了Dot ELISA、Sandwich ELISA和R IHA 3种CAg检测方法 ,用吡喹酮 (50mg·kg- 1,顿服 )治疗日本血吸虫病人 ,进行治疗后不同时期的同步血清学检测 ,并评估检测结果。结果 :吡喹酮治疗后半年 ,上述 3种检测方法的CAg阴转率分别为 75 .8%、72 .6 %和43.5% (P <0 .0 1 ) ,治疗后 1年分别为 83.9%、88.7%和 71 .0 % (P <0 .0 5) ;治疗后 2年分别为87.1 %、95 .2 %和 93 .5 % (P >0 .0 5) ;CAg阳性病例的平均抗原滴度倒数 (GMRT)随治疗后时间的延长逐步下降 ,治疗后 2年三种方法均达到各自的最低阳性稀释度。结论 :考核吡喹酮治疗日本血吸虫病人近期 (半年或 1年 )疗效 ,Dot ELISA和Sandwich ELISA均较好 ,但后者在结果判读上较前者更为客观 ;考核远期 (2年 )疗效 ,3种方法的检测结果无显著性差别 ;
AIM: To compare 3 different methods of detecting the circula ti ng antigen (CAg) to evaluate the chemotherapeutic effect in treatment with patie nts with schistosomiasis Japonica by praziquantel. METHODS: Seru m CAg was detected in patients by Dot-ELISA, Sandwich-ELISA and R-IHA, based on monoclonal antibody (MAb) JPG 3.The reverse negative rates were analyzed at six months, one year and two years after treatment with praziquantel 50 mg·kg -1 (one dosage). RESULTS: The reverse negative rates of C Ag in serum treated with praziquantel were 75.8 %, 72.6 % and 43.5 % at six months (P< 0.01 ), 83.9 %, 88.7 % and 71.0 % at one year (P< 0.05 ), and 87.1 %, 95.2 % and 93.5 % at two years (P> 0.05 ) by Dot-ELISA, Sandwich-ELISA and R- IHA, respectively. The geometric mean reciprocal titer (GMRT) in positive in dividuals declined constantly at six months, one year and two years. CON CLUSION: Dot-ELISA and Sandwich-ELISA are better than R-IHA in evalu ation of chemotherapy effect of praziquantel at six months and one year, whereas Sandwich-ELISA is more objective than Dot-ELISA for reading results. All of t hree assays have no significant difference after two years of treatment. The GMR T that reflects circulating antigen level can also assess the cure after chemoth erapy with praziquantel to a certain extent.
出处
《中国临床药理学与治疗学》
CAS
CSCD
2004年第2期177-179,共3页
Chinese Journal of Clinical Pharmacology and Therapeutics
关键词
吡喹酮
血吸虫病
循环抗原
疗效考核
单克隆抗体
praziquantel
schistosomiasis
circulating antigen
evaluatio n of chemotherapy effect
monoclonal antibody
